Benzinga | Nov 2, 2021 10:50AM EDT

Raymond James Maintains Outperform on Neurocrine Biosciences, Lowers Price Target to $150

Raymond James analyst Danielle Brill maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and lowers the price target from $163 to $150.